# A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

Source: https://onco.cc/trials/nct03790111/  
OnCo record `nct03790111` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Telotristat ethyl in Biliary tract cancer and Biliary tract cancer, run by TerSera Therapeutics LLC, recorded as terminated on the registry.

## Summary

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT03790111 by TerSera Therapeutics LLC, with 53 participants recorded, started 2019-03-13 and due to reach its primary completion in 2022-01-13. Interventions recorded: telotristat ethyl. Conditions recorded: Biliary Tract Cancer (BTC).

Linked to the drug Telotristat ethyl because the registry names it among its interventions and Biliary tract cancer and Biliary tract cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03790111
- Phase: 2
- Setting: A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)
- Sponsor: TerSera Therapeutics LLC
- Enrolled: 53

## Sources

- ClinicalTrials.gov NCT03790111: https://clinicaltrials.gov/study/NCT03790111

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [Telotristat ethyl](https://onco.cc/drugs/telotristat-ethyl/)
- companies: [TerSera Therapeutics](https://onco.cc/companies/tersera-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct03790111.json